WCG Wealth Advisors LLC increased its holdings in shares of Sanofi (NASDAQ:SNY – Free Report) by 132.7% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 61,255 shares of the company’s stock after purchasing an additional 34,931 shares during the quarter. WCG Wealth Advisors LLC’s holdings in Sanofi were worth $2,969,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Flagship Harbor Advisors LLC acquired a new stake in shares of Sanofi in the fourth quarter worth $25,000. Measured Wealth Private Client Group LLC acquired a new stake in Sanofi in the 3rd quarter valued at $29,000. Palisade Asset Management LLC purchased a new position in Sanofi in the third quarter valued at about $30,000. Annis Gardner Whiting Capital Advisors LLC boosted its position in shares of Sanofi by 544.4% in the fourth quarter. Annis Gardner Whiting Capital Advisors LLC now owns 696 shares of the company’s stock worth $34,000 after buying an additional 588 shares during the period. Finally, Larson Financial Group LLC grew its stake in shares of Sanofi by 48.9% in the fourth quarter. Larson Financial Group LLC now owns 810 shares of the company’s stock valued at $39,000 after buying an additional 266 shares in the last quarter. 14.03% of the stock is owned by institutional investors and hedge funds.
Sanofi Price Performance
Shares of NASDAQ SNY opened at $44.38 on Friday. The business has a 50 day simple moving average of $45.47 and a 200-day simple moving average of $46.77. Sanofi has a twelve month low of $42.28 and a twelve month high of $52.68. The company has a market capitalization of $107.60 billion, a price-to-earnings ratio of 12.40, a price-to-earnings-growth ratio of 1.04 and a beta of 0.34. The company has a current ratio of 1.01, a quick ratio of 0.22 and a debt-to-equity ratio of 0.17.
Sanofi Increases Dividend
Analysts Set New Price Targets
A number of analysts have recently issued reports on SNY shares. Wall Street Zen lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 21st. Weiss Ratings upgraded shares of Sanofi from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, May 13th. Morgan Stanley set a $52.00 price target on Sanofi in a research note on Friday, May 1st. Bank of America cut Sanofi from a “buy” rating to a “neutral” rating in a research note on Thursday, February 12th. Finally, Citigroup reissued a “neutral” rating on shares of Sanofi in a report on Monday, April 13th. Two investment analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and ten have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Sanofi has an average rating of “Hold” and an average target price of $51.00.
View Our Latest Stock Report on SNY
About Sanofi
Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.
Key commercial offerings include specialty biologics and established small-molecule medicines.
Featured Stories
- Five stocks we like better than Sanofi
- The Great AI Server Rotation Puts Hewlett Packard Enterprise and Super Micro Computer in Focus
- Generac’s AI Power Pivot Raises a Bigger Question About Data Center Demand
- Medtronic Bottoms, Healthy Rebound Ahead
- GitLab’s Price Recovery Gains Traction—Time to Get On Board?
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY – Free Report).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.
